Postoperative pharmacotherapy for patients with biliary atresia in Japan.
UDCA
biliary atresia
nationwide survey
pharmacotherapy
trimethoprim-sulfamethoxazole
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
07
09
2021
received:
16
09
2020
accepted:
13
09
2021
pubmed:
17
9
2021
medline:
24
3
2022
entrez:
16
9
2021
Statut:
ppublish
Résumé
Members of the Japanese Biliary Atresia Society were surveyed using questionnaires that assess their current practice regarding postoperative pharmacotherapy for outpatients with biliary atresia (BA). In September 2018, questionnaires were sent to 100 member institutions of the Japanese Biliary Atresia Society. Questionnaires included the number of BA outpatients per institution and pharmacotherapy for outpatients with native liver. Pharmacotherapies were categorized into antibiotics, cholagogues, hepatoprotective agents, branched-chain amino acid supplement, Japanese Kampo medicine, probiotics, laxative, glycerin enema, and "others." In each category, the questionnaires asked about the medicine's details and the time of withdrawal of administration. Responses were collected from 58 of the 100 institutions. Fifty-four institutions (94.7%) had prescribed one or more medicines as postoperative pharmacotherapy, and three institutions (5.3%) did not prescribe any medicines. Fifty-three institutions (93.0%) had prescribed ursodeoxycholic acid (UDCA), and 32 (60.4%) of these continued prescribing UDCA as long as the condition of patients remained unchanged. Twenty-nine (50.9%) had prescribed Japanese Kampo medicines ("Inchinkoto" in all cases). Twenty-four (42.1%) had prescribed antibiotics, mainly trimethoprim-sulfamethoxazole, in 21 (87.5%). Twenty-three (40.4%) had prescribed probiotics. There were many variations of pharmacotherapy in BA outpatients with native liver in Japan, including antibiotic, probiotic, and Inchinkoto prescriptions. Of the various drugs, the most commonly administered was UDCA.
Sections du résumé
BACKGROUND
BACKGROUND
Members of the Japanese Biliary Atresia Society were surveyed using questionnaires that assess their current practice regarding postoperative pharmacotherapy for outpatients with biliary atresia (BA).
METHODS
METHODS
In September 2018, questionnaires were sent to 100 member institutions of the Japanese Biliary Atresia Society. Questionnaires included the number of BA outpatients per institution and pharmacotherapy for outpatients with native liver. Pharmacotherapies were categorized into antibiotics, cholagogues, hepatoprotective agents, branched-chain amino acid supplement, Japanese Kampo medicine, probiotics, laxative, glycerin enema, and "others." In each category, the questionnaires asked about the medicine's details and the time of withdrawal of administration.
RESULTS
RESULTS
Responses were collected from 58 of the 100 institutions. Fifty-four institutions (94.7%) had prescribed one or more medicines as postoperative pharmacotherapy, and three institutions (5.3%) did not prescribe any medicines. Fifty-three institutions (93.0%) had prescribed ursodeoxycholic acid (UDCA), and 32 (60.4%) of these continued prescribing UDCA as long as the condition of patients remained unchanged. Twenty-nine (50.9%) had prescribed Japanese Kampo medicines ("Inchinkoto" in all cases). Twenty-four (42.1%) had prescribed antibiotics, mainly trimethoprim-sulfamethoxazole, in 21 (87.5%). Twenty-three (40.4%) had prescribed probiotics.
CONCLUSIONS
CONCLUSIONS
There were many variations of pharmacotherapy in BA outpatients with native liver in Japan, including antibiotic, probiotic, and Inchinkoto prescriptions. Of the various drugs, the most commonly administered was UDCA.
Substances chimiques
Cholagogues and Choleretics
0
Ursodeoxycholic Acid
724L30Y2QR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14990Informations de copyright
© 2021 Japan Pediatric Society.
Références
Nio M. Japanese biliary atresia registry. Pediatr. Surg. Int. 2017; 33: 1319-25.
Muraji T, Nio M, Ohhama Y et al. Postoperative corticosteroid therapy for bile drainage in biliary atresia-a nationwide survey. J. Pediatr. Surg. 2004; 39: 1803-5.
Ando H, Inomata Y, Iwanaka T et al. Clinical practice guidelines for biliary atresia in Japan: a secondary publication of the abbreviated version translated into English. J. Hepatobiliary Pancreat. Sci. 2021; 28: 55-61.
Kumagi T, Drenth JP, Guttman O et al. Biliary atresia and survival into adulthood without transplantation: a collaborative multicenter clinic review. Liver Int. 2012; 32: 510-8.
Liu J, Dong R, Chen G, Dong K, Zheng S. Risk factors and prognostic effects of cholangitis after Kasai procedure in biliary atresia patients: a retrospective clinical study. J. Pediatr. Surg. 2019; 54: 2559-64.
Lally KP, Kanegaye J, Matsumura M, Rosenthal P, Sinatra F, Atkinson JB. Perioperative factors affecting the outcome following repair of biliary atresia. Pediatrics 1989; 83: 723-6.
Bu LN, Chen HL, Chang CJ et al. Prophylactic oral antibiotics in prevention of recurrent cholangitis after the Kasai portoenterostomy. J. Pediatr. Surg. 2003; 38: 590-3.
Nurjadi D, Zizmann E, Chanthalangsy Q, Heeg K, Boutin S. Integrative analysis of whole genome sequencing and phenotypic resistance toward prediction of Trimethoprim-Sulfamethoxazole resistance in Staphylococcus aureus. Front. Microbiol. 2021; 11: 607842.
de Vries W, de Langen ZJ, Groen H et al. Biliary atresia in the Netherlands: outcome of patients diagnosed between 1987 and 2008. J. Pediatr. 2012; 160: 638-44.
Nittono H, Tokita A, Hayashi M et al. Ursodeoxycholic acid therapy in the treatment of biliary atresia. Biomed. Pharmacother. 1989; 43: 37-41.
Willot S, Uhlen S, Michaud L et al. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia. Pediatrics 2008; 122: 1236-41.
Kotb MA. Review of historical cohort: ursodeoxycholic acid in extrahepatic biliary atresia. J. Pediatr. Surg. 2008; 43: 1321-7.
Miyazaki T, Matsuzaki Y. Taurine and liver diseases: a focus on the heterogeneous protective properties of taurine. Amino Acids 2014; 46: 101-10.
Aboutwerat A, Pemberton PW, Smith A et al. Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim. Biophys. Acta. 2003; 1637: 142-50.
Iinuma Y, Kubota M, Yagi M, Kanada S, Yamazaki S, Kinoshita Y. Effects of the herbal medicine Inchinko-to on liver function in postoperative patients with biliary atresia-a pilot study. J. Pediatr. Surg. 2003; 38: 1607-11.
Tamura T, Kobayashi H, Yamataka A, Lane GJ, Koga H, Miyano T. Inchin-ko-to prevents medium-term liver fibrosis in postoperative biliary atresia patients. Pediatr. Surg. Int. 2007; 23: 343-7.
Lien TH, Bu LN, Wu JF et al. Use of Lactobacillus casei rhamnosus to prevent cholangitis in biliary atresia after Kasai operation. J. Pediatr. Gastroenterol. Nutr. 2015; 60: 654-8.
Dong R, Sun S, Liu XZ, Shen Z, Chen G, Zheng S. Fat-soluble vitamin deficiency in pediatric patients with biliary atresia. Gastroenterol. Res. Pract. 2017; 2017: 7496860.
Shneider BL, Magee JC, Bezerra JA et al. Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia. Pediatrics 2012; 130: 607-14.
Feldman AG, Mack CL. Biliary atresia: clinical lessons learned. J. Pediatr. Gastroenterol. Nutr. 2015; 61: 167-75.
Guedes RR, Kieling CO, Dos Santos JL et al. Severity of ascites is associated with increased mortality in patients with cirrhosis secondary to biliary atresia. Dig. Dis. Sci. 2020; 65: 3369-77